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cal and cognitive ability, behaviour, co-morbidities, demographic
and socio-economic variables. The attending parent completed
the Child Health Questionnaire 50-item version (CHQ-50) for
children ≥5 years at baseline and 12 months. The Impact of 
Paediatric Epilepsy Scale (IPES) was used to measure burden on
families. RESULTS: 132 children were enrolled and data was
available on 127. The median age was 8.8 years and 54% were
male. 63% had partial seizures and 61% of all children had cryp-
togenic or symptomatic epilepsy. 53% of children had frequent
seizures (>10/month). 93 children ≥5 years were included in the
QOL analysis. Children with frequent seizures scored signiﬁ-
cantly worse than those with no/infrequent seizures on 10/14 and
11/14 of the CHQ-50 subscales tested and both IPES scores at
baseline and 12 months respectively. Children with crypto-
genic/symptomatic epilepsy scored signiﬁcantly worse than those
with idiopathic epilepsy. No such differences were found
between seizure types and there were no differences between
ﬁndings at baseline and 12 months. CONCLUSIONS: The
burden of epilepsy on children and their families is substantial.
Seizure frequency and epilepsy syndrome rather than seizure type
determines the impact.
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OBJECTIVE: To describe the incidence, prevalence and man-
agement of migraine in the UK. METHODS: The study consid-
ered patients >18 years with a record of migraine (diagnosed
migraine) or headache with a prescription for a triptan, ergot
alkaloid, prophylactic or a combined anti-emetic and analgesic
treatment (undiagnosed migraine), registered between
1994–2003 on the General Practice Research Database (GPRD)
covering 4.6% of the UK population. Incidence and prevalence
were estimated from the GPRD population, prescribing and
management trends were examined. RESULTS: A total of
108,652 migraine patients, average age 45 years, were identiﬁed;
76% were female. The incidence of migraine was 11/1000
person-years for females and 3/1000 person-years for males. The
female: male ratio was on average 3 :1. Prevalence over the 10-
year period was 6.9%, at the low end of rates reported in the
literature. Annual prevalence increased over time from 2.4% in
1995 to 4.5% in 2003. Among females peak prevalence is seen
in the 31–59 age group, for males this is 18–29. The percentage
of patients with undiagnosed migraine was stable at around 12%
over the period. The average annual number of migraine-related
GP consultations is 3 (95% CI 2–6). In diagnosed migraine, trip-
tans, anti-emetics and prophylactics are prescribed almost
equally at 34%, 31% and 33% respectively. In undiagnosed
migraine prophylactics (48%) are most prescribed. Younger
patients (<30) receive less triptans (19%) but more anti-emetics
(49%) than other age-groups. Ergots are rarely prescribed.
Triptan prescriptions increased from 19% in 1994 to 42% in
2003, excluding analgesics. CONCLUSION: Not all patients
will consult a GP for migraine explaining the low prevalence and
incidence rates. A substantial number of migraine patients are
not diagnosed. A peak prevalence in the productive age, high
annual consultation rates and high triptan prescription rates
suggest that migraine represents a sizeable economic burden to
the UK.
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OBJECTIVE: To carry out a one-year cost beneﬁt analysis from
the Year-2005 societal perspective of the acute migraine attacks
treatment in Spain. METHODS: A cost-beneﬁts analysis was
performed. Model data were obtained from the Spanish cohort
of a multinational survey assessing impact of migraine on dis-
ability, absenteeism and health care resource utilization. Beneﬁts
(days of disability and health resources use avoided) were com-
puted indirectly by imputation of the effectiveness (anti-migraine
complete response) obtained from a published efﬁcacy meta-
analysis of available triptans in Spain. Human capital method
was used for imputation indirect costs and beneﬁts. Results are
expressed as net beneﬁts. Sensibility analysis was performed.
RESULTS: The number of annual migraine attacks was 57.7
(95% conﬁdence interval: 44.5–77.2), the paid and unpaid
annual lost-workday-equivalents (LWDE) were 34.9 (22.8–68.3)
and 37.5 (27.0–54.1), respectively. The annual cost of untreated
migraine was €4077.70 (3145.1–5451.0). Migraine treatment
reduced the number of LWDEs per year between 7.5 (5.2–12.7)
with zolmitriptan-2.5, to 14.7 (10.1–24.8) with eletriptan-40
and rizatriptan-10. Compared with no-treatment, the average
annual net beneﬁts obtained were: eletriptan-40; €269.50
(207.9–360.3), rizatriptan-10; €226.20 (174.5–302.4), suma-
triptan-50; €185.80 (143.3–248.4); naratriptan-2.5; €126.40
(97.5–169.0), and almotriptan-12.5; €8.40 (6.4–11.2).
Zolmitriptan-2.5, zolmitriptan-5, and sumatriptan-100 showed
no net beneﬁts. Results were robust to the sensitivity analyses
throughout different scenarios (number of migraine attacks,
salary, cost of migraine attack), except when minimal ofﬁcial
salary was used in the model. CONCLUSIONS: Compared with
existing triptans, eletriptan-40 showed the higher monetary net
beneﬁt over the untreated migraine attack alternative, yielding
more savings to the Society.
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OBJECTIVE: To perform cost-effectiveness analysis of betahis-
tine vs. cinnarizine for vertigo in Russia. METHODS: A total of
240 patients with vertigo were randomized for betahistine 16mg
3 times a day (group B) or cinnarizine 25mg 3 times a day (group
C) for 3 months. 11 parameters of health status and functional
abilities (such as dizziness, nausea, ability to use public transport
and others) were measured before the study and by the end of
each month using 5-score scale. Absence of severe and moderate
functional disabilities (3 scores and more) for all 11 parameters
by the end of treatment was the criteria of effectiveness. Direct
medical costs were taken into account from the health care
system point of view. RESULTS: A total of 215 patients ﬁnished
the study. There was signiﬁcant positive dynamics in both groups
but in group B positive changes occurred earlier and were more
expressed. 86% (95% CI 79.5–92.5%) of patients in B group
and 39% (95% CI 29.6–48.4%) in group C had no severe and
moderate functional disabilities by the end of study. Median
direct cost was 9177.2 rubles ($328 USD) in group B and 6425.6
rubles ($229) in group C. Betahistine was signiﬁcantly more
effective and more costly. Incremental CER was 5854.47 extra
